Amoxicillin Long
Phase 3Small molecule
Amoxicillin Long is one of 11 small molecule programs targeting Antibiotic. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Antibiotic
#DrugCompanyPhaseTrials
1Acanya
PfizerApproved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Levaquin
WWim Janssens
Approved
Rocephin
CConrado Roberto Hoffmann Filho
Phase 3
Cefzil
CCordenpharma
Approved
Amoxicillin-Clavulanate
IIterum Therapeutics, International Limited
Phase 3
Co-Amoxiclav
IImperial College London
Phase 3
Amoxicillin Long
UUniversita degli Studi di Genova
Phase 3
Keflex
Eli LillyPreclinical
Ancef
BBaxter Healthcare Corporation
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Amoxicillin Long. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversita degli Studi di Genova